The estimated Net Worth of Jane Wright Mitchell is at least $639 Thousand dollars as of 16 August 2021. Ms Mitchell owns over 2,500 units of Vaxcyte stock worth over $638,719 and over the last 10 years she sold PCVX stock worth over $0.
Ms has made over 5 trades of the Vaxcyte stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 2,500 units of PCVX stock worth $5,075 on 16 August 2021.
The largest trade she's ever made was exercising 10,000 units of Vaxcyte stock on 12 August 2021 worth over $20,300. On average, Ms trades about 1,818 units every 19 days since 2014. As of 16 August 2021 she still owns at least 5,625 units of Vaxcyte stock.
You can see the complete history of Ms Mitchell stock trades at the bottom of the page.
Jane Wright-Mitchell J.D., Pharm.D. is the Gen. Counsel at Vaxcyte.
Ms D is 50, she's been the Gen. Counsel of Vaxcyte since . There are 7 older and 3 younger executives at Vaxcyte. The oldest executive at Vaxcyte, Inc. is Paul W. Sauer M.B.A., MBA, 60, who is the Sr. VP of Process Devel. & Manufacturing.
Jane's mailing address filed with the SEC is C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY, CA, 94404.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., and Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: